Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.

Baily ThomasMadison BurnsHelen PervanasDaniel CiurescuLorena Dima

Published in: American journal of therapeutics (2023)

The novel mechanism and improvement in progression-free survival compared with standard of care highlight the therapeutic advancement of nivolumab/relatlimab-rmbw in the treatment of unresectable and metastatic melanoma.

Keyphrases

combination therapy
free survival
locally advanced
liver metastases
healthcare
palliative care
quality improvement
radiation therapy
pain management
chronic pain